Sunday, July 12, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 40 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 10227323

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted
  2. US 10227312

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted
  3. US 10221161

    Inhibitors of plasma kallikrein

    KalVista Pharmaceuticals Limited · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  4. US 10221174

    N-(phenylsulfonyl)benzamides and related compounds as BCL-2 inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  5. US 10214509

    Amino-substituted heterocyclic derivatives as sodium channel inhibitors

    Almirall, S.A. · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  6. US 10214522

    Anti-alphavbeta1 integrin inhibitors and methods of use

    The Regents of the University of California · Granted Feb 26, 2019 · Expires Feb 21, 2039

    granted
  7. US 2019055264

    Macrocyclic MCL-1 inhibitors and methods of use

    ABBVIE INC [US] · Granted Feb 21, 2019 · Expires Feb 16, 2039

    granted
  8. US 10206924

    Small molecule inhibitors of EGFR and PI3K

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted
  9. US 10208040

    Fused imidazo-piperidine JAK inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted
  10. US 10202340

    Glucosylceramide synthase inhibitors and therapeutic methods using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  11. US 10202366

    Methods of promoting wound healing using CRM1 inhibitors

    Karyopharm Therapeutics Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted
  12. US 10195214

    Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors

    Corcept Therapeutics Incorporated · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  13. US 10196424

    Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

    Protagonist Therapeutics, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  14. US 10196393

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  15. US 10196378

    Inhibitors of BCR-ABL mutants and use thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted
  16. US 10189823

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  17. US 10189784

    N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase

    ACADEMISCH MEDISCH CENTRUM · Granted Jan 29, 2019 · Expires Jan 24, 2039

    granted
  18. US 10183933

    Isoindolinone inhibitors of phosphatidylinositol 3-kinase

    Vertex Pharmaceuticals Incorporated · Granted Jan 22, 2019 · Expires Jan 17, 2039

    granted
  19. US 10174018

    Protein kinase inhibitors

    Princeton Drug Discovery, Inc · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  20. US 10172789

    Compositions for transdermal delivery of mTOR inhibitors

    PALVELLA THERAPEUTICS, INC. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  21. US 10172840

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  22. US 10172844

    Use of CDK9 inhibitors to reduce cartilage degradation

    The Regents of the University of California · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  23. US 10173985

    Aminoindazole derivatives as sodium channel inhibitors

    Almirall, S.A. · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  24. US 10167292

    Benzodiazepines as bromodomain inhibitors

    Catalyst Therapeutics Pty Ltd. · Granted Jan 1, 2019 · Expires Dec 27, 2038

    granted